.
According to Iden, the reasons for the expected turnaround are manifold. “Together with the shareholders, we have developed a focused strategy and, with our management team, are implementing numerous efficiency programmes with increasing success.” Basically, permanent quality leadership is aimed at for the selected target industries, which should facilitate profitable growth. In this way, trans-o-flex, during its recent Pharma Logistics Day, had presented the basic points of the new pharma logistics strategy with its focus on active temperature control for all of its transports of pharmaceuticals as well as the GDP+ digitalisation campaign. On this basis, the new management team, which, in addition to CEO Frank Iden, consists of Wolfgang Weber (COO), Dr Sven Rutkowsky (CRO) and Axel Stetenfeld (CFO), intends to secure and strengthen trans-o-flex’ USPs. “In Germany, active temperature control for the transportation of pharmaceuticals is increasingly becoming the standard solution and trans-o-flex is the only service provider with a nationwide network suitable for such a distribution”, continues Iden. “With Amberger and Schoeller, we have very competent shareholders that are quick to make decisions and have already given the go-ahead for trans-o-flex’ planned growth and expansion plans.” By 2018, the company intends to invest more than EUR 56 million in IT, vehicles, transhipment centres and staff training. With respect to its costs, the company, following an uncompromising analysis of the contribution profit margin, decided to discontinue the transportation of loss-making shipment volumes and the co-operation with unprofitable customers. “The trans-o-flex Logistics Group of tomorrow will be more efficient than today and, with high standards and innovative quality products, it will ensure the maximum benefit for its customers”.
- Reorganisation plan takes effect: adjusted customer and product portfolios, improved operational quality, reduced costs
- Board of Directors expects a positive total result for 2017
- Go-ahead for investments to the amount of EUR 56 million
According to Iden, the reasons for the expected turnaround are manifold. “Together with the shareholders, we have developed a focused strategy and, with our management team, are implementing numerous efficiency programmes with increasing success.” Basically, permanent quality leadership is aimed at for the selected target industries, which should facilitate profitable growth. In this way, trans-o-flex, during its recent Pharma Logistics Day, had presented the basic points of the new pharma logistics strategy with its focus on active temperature control for all of its transports of pharmaceuticals as well as the GDP+ digitalisation campaign. On this basis, the new management team, which, in addition to CEO Frank Iden, consists of Wolfgang Weber (COO), Dr Sven Rutkowsky (CRO) and Axel Stetenfeld (CFO), intends to secure and strengthen trans-o-flex’ USPs. “In Germany, active temperature control for the transportation of pharmaceuticals is increasingly becoming the standard solution and trans-o-flex is the only service provider with a nationwide network suitable for such a distribution”, continues Iden. “With Amberger and Schoeller, we have very competent shareholders that are quick to make decisions and have already given the go-ahead for trans-o-flex’ planned growth and expansion plans.” By 2018, the company intends to invest more than EUR 56 million in IT, vehicles, transhipment centres and staff training. With respect to its costs, the company, following an uncompromising analysis of the contribution profit margin, decided to discontinue the transportation of loss-making shipment volumes and the co-operation with unprofitable customers. “The trans-o-flex Logistics Group of tomorrow will be more efficient than today and, with high standards and innovative quality products, it will ensure the maximum benefit for its customers”.
